Compare Fabrinet (FN) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs Humana Inc — how do they compare? Fabrinet trades at $470.67 (market cap $17.44B), while Humana Inc trades at $397.7 (market cap $48.96B). The key difference: Humana Inc is far larger — about 2.8× Fabrinet's market cap, and Humana Inc pays a 0.87% dividend while Fabrinet pays none. Which is the better fit depends on your goals.
| FN | HUM | |
|---|---|---|
Market Cap | $17.44B | $48.96B |
Sector | Technology | Health |
52-Week High | $746.47 | $409.42 |
52-Week Low | $277.04 | $163.67 |
Enterprise Value | $16.50B | $58.00B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $474.19, down 1.78% on the day, with a bearish technical signal despite strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.72 exceeding expectations. Analyst consensus remains strongly bullish with a $733 price target, though technical indicators show selling pressure with support at $473 and resistance at $484.
FN presents a compelling growth story driven by AI infrastructure demand, with revenue projected to grow from $3.42B to $4.2B in 2026. However, premium valuation metrics (P/E 41.81, P/B 7.57) and technical bearishness create near-term headwinds. The risk-reward favors long-term investors given the company's strategic positioning in optical communications and debt-free balance sheet.
Humana (HUM) trades at $406.70, up 0.17% on the day, and is currently above its consensus price target. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company has beaten earnings expectations for three consecutive quarters and is executing a strategic shift from membership growth to profitability, targeting a 3% Medicare Advantage margin by 2028. Revenue has grown consistently from $92.9B in 2022 to $129.7B in 2025.
The outlook is mixed. The company's strategic pivot and recent contract wins like the Illinois Medicaid contract present growth opportunities. However, significant risks include multiple legal investigations into statements on healthcare costs, declining net profit margins (from 3.02% in 2022 to 0.91% in 2025), and a high P/E ratio of 43.52. Analyst sentiment is cautious, with a majority 'Hold' rating and a consensus price target 13% below the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
